Evidence map›Paper›PMID 31164314›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2019

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype.

Lisa Vermunt, Sietske A M Sikkes, Ardo van den Hout, Ron Handels, Isabelle Bos, Wiesje M van der Flier, Silke Kern, Pierre-Jean Ousset, Paul Maruff, Ingmar Skoog and 15 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05153941 (DNS Cohort Study Aimed at Understanding the Pathophysiology of AD and AD Related Disorders), which is not on this map. Cited by 311 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
311citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05153941 active not recruitingnot on this mapstarted 2022, after this paper: background citation

DNS Cohort Study Aimed at Understanding the Pathophysiology of AD and AD Related Disorders (ADRD)

TypeobservationalSponsorAltoidaRan2022 to 2030Enrolled3,500ConditionsAlzheimer's Disease, Mild Cognitive Impairment
3 · Its place in the literature

Who cites it

311 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. The Effects of Pomegranate Seed Oil on Mild Cognitive Impairment.Journal of Alzheimer's disease : JAD · 2024
    Trial
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Observational
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

251 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Lisa VermuntDepartment of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Electronic address: l.vermunt@vumc.nl.
Sietske A M SikkesDepartment of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Ardo van den HoutDepartment of Statistical Science, University College London, London, UK.
Ron HandelsDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS), Alzheimer Centrum Limburg, Maastricht University, Maastricht, The Netherlands.
Isabelle BosDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS), Alzheimer Centrum Limburg, Maastricht University, Maastricht, The Netherlands.
Wiesje M van der FlierDepartment of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Silke KernDepartment of Psychiatry and Neurochemistry, Neuropsychiatric Epidemiology Unit, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Pierre-Jean OussetCHU Toulouse, Gérontopôle and INSERM UMR 1027, Toulouse, France.
Paul MaruffCogstate Ltd, Florey Institute, University of Melbourne, Melbourne, Australia.
Ingmar SkoogDepartment of Psychiatry and Neurochemistry, Neuropsychiatric Epidemiology Unit, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Frans R J VerheyDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS), Alzheimer Centrum Limburg, Maastricht University, Maastricht, The Netherlands.
Yvonne Freund-LeviDepartment of Neurobiology, Caring Sciences and Society (NVS), Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Old Age Psychiatry, Psychology and Neuroscience, King's College London, London, UK; School of Medical Sciences, Orebro University Campus USÖ, Örebro, Sweden.
Magda Tsolaki3rd Department of Neurology, Aristotle University of Thessaloniki, Memory and Dementia Center, "G Papanicolau" General Hospital, Thessaloniki, Greece.
Åsa K WallinDepartment of Clinical Sciences, Clinical Memory Research Unit, Lund University, Malmö, Sweden.
Marcel Olde RikkertDepartment of Geriatric Medicine, Radboudumc Alzheimer Centre, Radboud University Medical Center, Nijmegen, The Netherlands.
Hilkka SoininenInstitute of Clinical Medicine, Neurology, University of Eastern Finland, Kuopio, Finland.
Luisa Spiru"Carol Davila" University of Medicine and Pharmacy, Geriatrics-Gerontology and Old Age Psychiatry Clinical Department -"Elias" University Clinical Hospital, Bucarest, Romenia; "Ana Aslan" International Academy of Aging - The Memory Clinic and Longevity Medicine, Bucarest, Romenia.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; UK Dementia Research Institute at UCL, London, UK.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Philip ScheltensDepartment of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Graciela Muniz-TerreraCentre for Dementia Prevention, University of Edinburgh, Edinburgh, UK.
Pieter Jelle VisserDepartment of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS), Alzheimer Centrum Limburg, Maastricht University, Maastricht, The Netherlands.
Alzheimer Disease Neuroimaging Initiative
AIBL Research Group
ICTUS/DSA study groups

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Study Coordination and Measurement CoreP01AG043362 · NIA · OREGON HEALTH & SCIENCE UNIVERSITY · PI HOFER, SCOTT M. · 2013 to 2017
$7.8M
NIA NIH HHS P01 AG043362NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

introductionWe estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (APOE) genotype, and cerebrospinal fluid tau on disease duration.

methodsWe performed multistate modeling in a combined sample of 6 cohorts (n = 3268) with death as the end stage and estimated the preclinical, prodromal, and dementia stage duration.

resultsThe overall AD duration varied between 24 years (age 60) and 15 years (age 80). For individuals presenting with preclinical AD, age 70, the estimated preclinical AD duration was 10 years, prodromal AD 4 years, and dementia 6 years. Male sex, clinical setting, APOE ε4 allele carriership, and abnormal cerebrospinal fluid tau were associated with a shorter duration, and these effects depended on disease stage. DISCUSSION: Estimates of AD disease duration become more accurate if age, sex, setting, APOE, and cerebrospinal fluid tau are taken into account. This will be relevant for clinical practice and trial design.

Indexed as

Alzheimer DiseaseAmyloidDisease ProgressionProdromal SymptomsAgedAllelesApolipoprotein E4BiomarkersCognitive DysfunctionFemaleGenotypeHumansLongitudinal StudiesMalePositron-Emission TomographySex FactorsAmyloidApolipoprotein E4Biomarkerstau ProteinsAlzheimer's diseaseAPOEClinical settingDementiaDisease durationMultistate modelPreclinicalProdromalProgression

Identifiers

PMID31164314
PMCPMC6646097

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.